Form 8-K - Current report:
SEC Accession No. 0001516551-25-000046
Filing Date
2025-06-11
Accepted
2025-06-11 17:13:32
Documents
14
Period of Report
2025-06-06
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20250606.htm   iXBRL 8-K 55022
2 EX-16.1 ex161-changeofaccountantsl.htm EX-16.1 2966
  Complete submission text file 0001516551-25-000046.txt   177772

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20250606.xsd EX-101.SCH 2058
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT skye-20250606_def.xml EX-101.DEF 2386
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20250606_lab.xml EX-101.LAB 21921
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20250606_pre.xml EX-101.PRE 12620
16 EXTRACTED XBRL INSTANCE DOCUMENT skye-20250606_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42009 | Film No.: 251040843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)